HC Wainwright & Co. Maintains Neutral on Aprea Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Andrew Fein maintains Aprea Therapeutics (NASDAQ:APRE) with a Neutral and lowers the price target from $6 to $4.
RBC Capital Maintains Sector Perform on Aprea Therapeutics, Lowers Price Target to $5
RBC Capital analyst Gregory Renza maintains Aprea Therapeutics (NASDAQ:APRE) with a Sector Perform and lowers the price target from $6 to $5.
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
Morgan Stanley Downgrades Aprea Therapeutics to Underweight, Lowers Price Target to $3
Morgan Stanley analyst Jeffrey Hung downgrades Aprea Therapeutics (NASDAQ:APRE) from Equal-Weight to Underweight and lowers the price target from $5 to $3.
Aprea Therapeutics Q2 EPS $(0.48) Up From $(0.78) YoY
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.48) per share. This is a 38.46 percent increase over losses of $(0.78) per share from the same period last year.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 83 companies set new 52-week lows.